Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Variation in HIV-1 Tat activity is a key determinant in the establishment of latent infection
Francisco Gomez-Rivera, … , Marianne E. Yaple-Maresh, Kathleen L. Collins
Francisco Gomez-Rivera, … , Marianne E. Yaple-Maresh, Kathleen L. Collins
Published December 5, 2024
Citation Information: JCI Insight. 2025;10(2):e184711. https://doi.org/10.1172/jci.insight.184711.
View: Text | PDF
Research Article Infectious disease Virology

Variation in HIV-1 Tat activity is a key determinant in the establishment of latent infection

  • Text
  • PDF
Abstract

Despite effective treatment, human immunodeficiency virus (HIV) persists in optimally treated people as a transcriptionally silent provirus. Latently infected cells evade the immune system and the harmful effects of the virus, thereby creating a long-lasting reservoir of HIV. To gain a deeper insight into the molecular mechanisms of HIV latency establishment, we constructed a series of HIV-1 fluorescent reporter viruses that distinguish active versus latent infection. We unexpectedly observed that the proportion of active to latent infection depended on a limiting viral factor, which created a bottleneck that could be overcome by superinfection of the cell, T cell activation, or overexpression of HIV-1 transactivator of transcription (Tat). In addition, we found that tat and regulator of expression of virion proteins (Rev) expression levels varied among HIV molecular clones and that tat levels were an important variable in latency establishment. Lower rev levels limited viral protein expression whereas lower Tat levels or mutation of the Tat binding element promoted latent infection that was resistant to reactivation even in fully activated primary T cells. Nevertheless, we found that combinations of latency reversal agents targeting both cellular activation and histone acetylation pathways overcame deficiencies in the Tat/TAR axis of transcription regulation. These results provide additional insight into the mechanisms of latency establishment and inform Tat-centered approaches to cure HIV.

Authors

Francisco Gomez-Rivera, Valeri H. Terry, Cuie Chen, Mark M. Painter, Maria C. Virgilio, Marianne E. Yaple-Maresh, Kathleen L. Collins

×

Figure 2

89.6 VT1 identifies reversible latency in primary human HSPCs.

Options: View larger image (or click on image) Download as PowerPoint
89.6 VT1 identifies reversible latency in primary human HSPCs.
(A) Schem...
(A) Schematic of the experimental process for B–E. (B) Flow cytometric analysis of HSPCs expanded, transduced, and sorted according to the timeline shown in A. As indicated, actively infected cells were removed via FACS by sorting latently infected (GFP+mCherry–) cells. The isolated cells were mixed with uninfected cells so that changes in the proportions of active and latent infection following LRA treatment could be more accurately quantified. (C and D) Flow cytometric analysis of HSPCs from B divided into 37°C or 30°C incubation conditions with LRAs as indicated for 24 hours. (E) Summary graph of flow cytometric analysis (C and D). Result is shown for 1 experiment. (F) Schematic of the experimental process for G and H. (G) Flow cytometric analysis of HSPCs expanded and transduced according to the timeline shown in F. (H) Summary graph of flow cytometric analysis performed as in G. Statistical significance was determined by 2-way ANOVA with Holm-Šídák multiple comparisons test. The mean ± standard deviation is shown for 3 independent experiments. ****P ≤ 0.0001. SSC, side scatter.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts